CureVac’s Final Chapter: A Surprise Profit Paves Way for BioNTech Takeover

CureVac is preparing to conclude its journey as an independent entity, but not before delivering a significant financial surprise. As shareholders gather for an extraordinary general meeting to finalize the company’s acquisition by BioNTech, the Tübingen-based firm has unexpectedly reported a profit—a development that few market observers anticipated. This raises important questions about the nature of these earnings and whether the merger is now certain to proceed.

The path toward acquisition has cleared a major regulatory hurdle with Germany’s Federal Cartel Office granting unconditional approval for the transaction. Attention now shifts entirely to today’s shareholder vote on the restructuring measures required to integrate CureVac into the Read more...